UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach

 
• By Eliza Slawther
  
Qalsody, an orphan medicine, is expected to be suitable for just 60 patients with ALS in the UK (Shutterstock)

More from Approval Standards

More from United Kingdom